A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05086692|
Recruitment Status : Recruiting
First Posted : October 21, 2021
Last Update Posted : November 3, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Advanced Solid Tumor Unresectable Solid Tumor Melanoma Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma Triple Negative Breast Cancer Cutaneous Melanoma Non-Small Cell Lung Cancer Squamous Non-Small Cell Lung Cancer Non-squamous Colorectal Cancer Gastric Cancer Biliary Tract Cancer Gallbladder Cancer Cervical Cancer Basal Cell Carcinoma Bladder Cancer Merkel Cell Carcinoma Squamous Cell Carcinoma of Head and Neck Cutaneous Squamous Cell Carcinoma Pleural Mesothelioma Esophageal Cancer Hepatocellular Carcinoma Endometrial Carcinoma Solid Tumor Solid Tumor, Adult||Drug: MDNA11 Monotherapy Drug: MDNA11 in combination with checkpoint inhibitor||Phase 1 Phase 2|
The study drug, MDNA11, is a selective IL-2 preferentially activating effector T cells (naïve CD8+ T-cells) and NK cells responsible for killing cancer cells, with minimal or no stimulation of the immunosuppressive Tregs. It is designed to potentially enhance host immune response and fusion to albumin increases the half-life further avoiding frequent dosing required with rhIL-2.
The study will be conducted at up to 16 clinical sites following regulatory authority and institutional review board / independent ethics committee (IRB/ IEC) approval and completion of informed consent. The study will be conducted in two parts:
- Sequential Dose Escalation
- Dose Expansion in monotherapy as well as with an immune checkpoint inhibitor.
Approximately 100 patients will be enrolled.
Tumor assessment by CT/MRI will be performed every 12 weeks and will continue until documented disease progression. Treatment may continue for up to 1 year, or until treatment discontinuation criteria are met. Patients can withdraw from participation at any time.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||Sequential dose escalation (MDNA11 monotherapy) followed by dose expansion with MDNA11 monotherapy as well as in combination with a CPI.|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors|
|Actual Study Start Date :||August 27, 2021|
|Estimated Primary Completion Date :||September 30, 2024|
|Estimated Study Completion Date :||December 30, 2024|
MDNA11 is a long-acting "beta-only" recombinant interleukin-2 (rIL-2) albumin fusion
Drug: MDNA11 Monotherapy
MDNA11 will be administered by the IV route on a once every 2 weeks (Q2W) dosing schedule.
Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the Recommended Phase 2 Dose (RP2D)
Other Name: Interleukin-2 (IL-2)-albumin
Drug: MDNA11 in combination with checkpoint inhibitor
MDNA11 in combination with checkpoint inhibitor Combination cohort is planned to evaluate the safety/ tolerability and anti-tumor activity of single agent MDNA11, or in combination with CPI in patients with solid tumors
Other Name: Interleukin-2 (IL-2)-albumin with checkpoint inhibitor
- Recommended Phase 2 Dose (RP2D) for MDNA11 [ Time Frame: 12 months ]Evaluation of tolerability as measured by number of patients with dose limiting toxicities (DLTs)
- Incidence of Treatment Related Adverse Events (TRAEs) [ Time Frame: 12 months ]Rate of TRAEs in patients with advanced solid tumors
- Incidence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: 12 months ]Rate of TEAEs in patients with advanced solid tumors
- Pharmacokinetic characteristics on MDNA11 - Cmax (ug/mL) [ Time Frame: Up to 12 months ]Maximum observed serum drug concentration
- Pharmacokinetic characteristics on MDNA11 - Tmax (h) [ Time Frame: Up to 12 months ]Time to maximum observed serum drug concentration
- Pharmacokinetic characteristics on MDNA11 - AUClast (h.ug/mL) [ Time Frame: Up to 12 months ]Area under the serum concentration vs time curve from time zero to the last measurable concentration
- Pharmacodynamic effects of MDNA11 [ Time Frame: Up to 12 months ]Measurement of translational parameters - Flow cytometry analysis of immune cells in blood and serum measurements of cytokine levels
- Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Overall Response Rate (ORR) [ Time Frame: Approximately 12 months ]Assessed by RECIST v1.1; CR+PR/Evaluable N
- Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Disease Control Rate (DCR) [ Time Frame: Approximately 12 months ]CR+PR+SD/Evaluable N
- Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Progression Free Survival (PFS) [ Time Frame: Approximately 12 months ]Time from signing ICF to disease progression
- Analysis of immune characteristics of the tumor microenvironment [ Time Frame: Up to 12 months ]Measured by change in Tumor Infiltrating Lymphocyte (TIL) levels
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Gender Based Eligibility:||Yes|
|Gender Eligibility Description:||Male Female (Women of Childbearing Potential will be subject to pregnancy testing)|
|Accepts Healthy Volunteers:||No|
Key Inclusion Criteria:
- Aged at least 18 years (inclusive at the time of informed consent).
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.
- Histologically or cytologically confirmed locally advanced or metastatic solid tumor that is unresectable (see tumor types listed under conditions)
- Demonstrated adequate organ function
- Measurable disease as per Response Evaluation Criteria in Solid Tumors, (RECIST v1.1) and documented by CT and/or MRI.
- Life expectancy of ≥ 12 weeks.
- Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and within 72 hours before the first dose of study drug(s). Women must not be breastfeeding.
- Agree to use highly effective contraception methods. WOCBP must agree to use highly effective birth control
Key Exclusion Criteria:
- Last administration of prior antitumor therapy or any investigational treatment within 28 days or less than 5 times the half-life, whichever is shorter. Palliative radiotherapy given within 28 days prior to the first dose of study drug may be approved on a case-by-case basis in discussion with the Sponsor.
- Has carcinomatous meningitis or leptomeningeal disease; stable CNS metastases permitted based on Medical Monitor review.
- Active malignancy (other than the disease under treatment in the study) within the previous 3 years except for curable cancers
- Clinically significant active, known or suspected autoimmune disease, or diseases that can be exacerbated with immunotherapy.
- Severe pulmonary, cardiac or other systemic disease.
- Females who are pregnant or lactating or planning to become pregnant during the study.
- Active infection requiring systemic therapy.
- Any medical, emotional or psychiatric condition that interfere with the patient's ability to adhere to the protocol
- Any other underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) unsafe or obscure the interpretation of toxicity determination or adverse events.
- Known severe hypersensitivity to any component of study drug(s).
- Prior Interleukin therapy.
- Inability to comply with study and follow up procedures as judged by the Investigator.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05086692
|Contact: Nina Merchantemail@example.com|
|Contact: Melissa Coellofirstname.lastname@example.org|
|United States, California|
|Providence Saint John's Health Center||Recruiting|
|Santa Monica, California, United States, 90404|
|United States, Florida|
|Boca Raton Regional Hospital||Recruiting|
|Boca Raton, Florida, United States, 33486|
|Orlando Health Cancer Institute||Recruiting|
|Orlando, Florida, United States, 32806|
|United States, Georgia|
|Emory - Winship Cancer Institute||Recruiting|
|Atlanta, Georgia, United States, 30322|
|Australia, New South Wales|
|Chris O'Brien Lifehouse||Recruiting|
|Camperdown, New South Wales, Australia, 2050|
|Scientia Clinical Research||Recruiting|
|Randwick, New South Wales, Australia, 2031|
|Gallipoli Medical Research Foundation||Recruiting|
|Greenslopes, Queensland, Australia, 4120|
|Princess Margaret Cancer Center||Recruiting|
|Toronto, Ontario, Canada, M4W 3E2|
|Study Director:||Nina Merchant||Medicenna Therapeutics|
|Study Chair:||Martin Bexon, MBBS||Medicenna Therapeutics|
|Responsible Party:||Medicenna Therapeutics, Inc.|
|Other Study ID Numbers:||
|First Posted:||October 21, 2021 Key Record Dates|
|Last Update Posted:||November 3, 2022|
|Last Verified:||October 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Mismatch Repair Deficient
Carcinoma, Merkel Cell
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Carcinoma, Renal Cell
Triple Negative Breast Neoplasms
Carcinoma, Basal Cell
Biliary Tract Neoplasms
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Digestive System Neoplasms
Digestive System Diseases
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue